458 Studies Now Enrolling
A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination with Endocrine and Targeted Therapies in Patients with Locally Advanced or Metastatic PIK3CA Mutant Hormone-Receptor Positive Breast Cancer
A Study for Patients with Locally Advanced or Metastatic Breast Cancer Using Study Drug GDC-0077
| Sponsor: | Genentech, Inc. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR0323 |
| U.S. Govt. ID: | NCT03006172 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of the study is to evaluate the safety and side effects of the study drug, GDC-0077. This study also looks for any anti-cancer activity of GDC-0077 alone in participants with locally advanced or metastatic breast cancer in postmenopausal women.
This study is closed
